Drug Profile
Research programme: controlled release pain therapeutics - POLYPID
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator POLYPID
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pain
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Postoperative-pain in Israel (Controlled release)
- 29 Mar 2017 Research programme: controlled release pain therapeutics - POLYPID is available for licensing as of 29 Mar 2017. http://www.polypid.com
- 29 Mar 2017 Early research in Postoperative pain in Israel (unspecified route)